loading
Jaguar Health Inc stock is traded at $2.58, with a volume of 17,887. It is up +0.39% in the last 24 hours and down -38.13% over the past month. Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
See More
Previous Close:
$2.57
Open:
$2.58
24h Volume:
17,887
Relative Volume:
0.13
Market Cap:
$4.84M
Revenue:
$10.48M
Net Income/Loss:
$-37.74M
P/E Ratio:
-0.1594
EPS:
-16.1846
Net Cash Flow:
$-29.03M
1W Performance:
-4.80%
1M Performance:
-38.13%
6M Performance:
-91.03%
1Y Performance:
-97.05%
1-Day Range:
Value
$2.5404
$2.60
1-Week Range:
Value
$2.43
$2.79
52-Week Range:
Value
$2.43
$110.75

Jaguar Health Inc Stock (JAGX) Company Profile

Name
Name
Jaguar Health Inc
Name
Phone
415-371-8300
Name
Address
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Name
Employee
49
Name
Twitter
@Jaguar_Health
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
JAGX's Discussions on Twitter

Compare JAGX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
JAGX
Jaguar Health Inc
2.58 4.84M 10.48M -37.74M -29.03M -16.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.62 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.36 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.91 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
543.48 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.49 28.51B 3.81B -644.79M -669.77M -6.24

Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-07-21 Initiated Cantor Fitzgerald Overweight
Jul-11-17 Initiated Rodman & Renshaw Buy

Jaguar Health Inc Stock (JAGX) Latest News

pulisher
Jun 18, 2025

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts - Marco Eagle

Jun 18, 2025
pulisher
Jun 17, 2025

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts | JAGX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Jaguar Health CEO Reveals Near-Term Catalysts at Emerging Growth Conference Tomorrow - Stock Titan

Jun 17, 2025
pulisher
Jun 13, 2025

Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - The Courier-Journal

Jun 13, 2025
pulisher
Jun 12, 2025

First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs - The Oklahoman

Jun 12, 2025
pulisher
Jun 11, 2025

Jaguar Health (JAGX) Advances Canalevia-CA1 Field Study for Cani - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

First Study Site Established for Jaguar Health Study of its FDA - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Jaguar Health Establishes First Site for Canalevia-CA1 Field Study - MarketScreener

Jun 11, 2025
pulisher
Jun 11, 2025

Jaguar Health (JAGX) Advances Canalevia-CA1 Field Study for Canine Treatment | JAGX Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs | JAGX Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

First FDA-Approved Dog Diarrhea Treatment Targets 6M Annual Cases with New Clinical Study - Stock Titan

Jun 11, 2025
pulisher
Jun 10, 2025

Jaguar Health, Inc. (NASDAQ:JAGX) Q1 2025 Earnings Call Transcript - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series - The Oklahoman

Jun 10, 2025
pulisher
Jun 10, 2025

Jaguar Health Reports First Quarter 2025 Financials - The Columbus Dispatch

Jun 10, 2025
pulisher
Jun 09, 2025

Jaguar Health Provides Update on Meeting with FDA Discussing Sta - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Jaguar Health Eyes FDA Orphan Drug Designation for Crofelemer By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer - Akron Beacon Journal

Jun 09, 2025
pulisher
Jun 09, 2025

REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners' Spring 2025 Spotlight Series | JAGX Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Jaguar Health to Reveal Critical FDA Feedback on Breakthrough Phase 3 Breast Cancer Trial Results - Stock Titan

Jun 09, 2025
pulisher
Jun 09, 2025

Jaguar Health (JAGX) Advances Plans for Crofelemer Application | - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

New to The Street's Documentary Specials Break Records: IMG Academy Surpasses 126,000 Views in Just 12 Days - The Columbus Dispatch

Jun 09, 2025
pulisher
Jun 09, 2025

Jaguar Health (JAGX) Advances Plans for Crofelemer Application | JAGX Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Jaguar Health Eyes FDA Orphan Drug Designation for Crofelemer - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

Breakthrough: FDA Meeting Could Fast-Track New Breast Cancer Treatment Following Positive Trial Data - Stock Titan

Jun 09, 2025
pulisher
Jun 09, 2025

Jaguar Health to Host Investor Call Monday, November 16th at 8:30 a.m. Eastern Regarding Q3 2020 Financials & Business Updates - ACCESS Newswire

Jun 09, 2025
pulisher
Jun 08, 2025

Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners’ Spring 2025 Spotlight Series - Detroit Free Press

Jun 08, 2025
pulisher
Jun 07, 2025

Small-cap biotech Jaguar Health’s stock jumps as it launches treatment for a painful side effect of cancer treatment - MSN

Jun 07, 2025

Jaguar Health Inc Stock (JAGX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.30
price down icon 0.68%
$36.37
price up icon 0.50%
$24.55
price up icon 8.53%
$97.80
price down icon 0.45%
$110.00
price up icon 1.61%
biotechnology ONC
$245.49
price up icon 0.48%
Cap:     |  Volume (24h):